SynthesisEpidemiology and infection2013
The Shigella human challenge model.
Synthesis in Epidemiology and infection, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06615375 (Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With the Shigella Tetravalent Bioconjugate Vaccine Shigella4V2), which is not on this map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With the Shigella Tetravalent Bioconjugate Vaccine Shigella4V2
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The increasing antimicrobial resistance ofPathogens and global health · 2023Pooled it
- Prevalence of Shigella species and its drug resistance pattern in Ethiopia: a systematic review and meta-analysis.Annals of clinical microbiology and antimicrobials · 2019Pooled it
- Review
- Review
- Shigella sonnei: epidemiology, evolution, pathogenesis, resistance and host interactions.Nature reviews. Microbiology · 2025Review
- Article
- The fusion subunit vaccine L-DBF protects aged mice against heterologous lethalFrontiers in immunology · 2025Article
- Transforming vaccinology.Cell · 2024Review
- Statistical design and analysis of controlled human malaria infection trials.Malaria journal · 2024Article
- Prevalence and changing antimicrobial resistance profiles of Shigella spp. isolated from diarrheal patients in Kolkata during 2011-2019.PLoS neglected tropical diseases · 2024Article
- Shigella-Controlled Human Infection Models: Current and Future Perspectives.Current topics in microbiology and immunology · 2024Review
- Quantitative dose-response analysis untangles host bottlenecks to enteric infection.Nature communications · 2023Article
- Further characterization ofFrontiers in immunology · 2023Article
- Controlled Human Infection Models To Accelerate Vaccine Development.Clinical microbiology reviews · 2022Review
- Establishment of a Controlled Human Infection Model with a Lyophilized Strain of Shigella sonnei 53G.mSphere · 2020Article
- Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G.mSphere · 2020Article
- An Oral Inoculation Infant Rabbit Model formBio · 2020Article
- Consensus Report on Shigella Controlled Human Infection Model: Conduct of Studies.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- Consensus Report on Shigella Controlled Human Infection Model: Introduction and Overview.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Shigella is an important bacterial cause of infectious diarrhoea globally. The Shigella human challenge model has been used since 1946 for a variety of objectives including understanding disease pathogenesis, human immune responses and allowing for an early assessment of vaccine efficacy. A systematic review of the literature regarding experimental shigellosis in human subjects was conducted. Summative estimates were calculated by strain and dose. While a total of 19 studies evaluating nine strains at doses ranging from 10 to 1 × 1010 colony-forming units were identified, most studies utilized the S. sonnei strain 53G and the S. flexneri strain 2457T. Inoculum solution and pre-inoculation buffering has varied over time although diarrhoea attack rates do not appear to increase above 75-80%, and dysentery rates remain fairly constant, highlighting the need for additional dose-ranging studies. Expansion of the model to include additional strains from different serotypes will elucidate serotype and strain-specific outcome variability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.